Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Average Recommendation of “Buy” from Analysts

by · The Cerbat Gem

Shares of Inhibikase Therapeutics, Inc. (NASDAQ:IKT – Get Free Report) have received an average rating of “Buy” from the five research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a strong buy recommendation to the company.

A number of research firms have recently weighed in on IKT. Wall Street Zen upgraded Inhibikase Therapeutics to a “sell” rating in a report on Saturday, December 27th. Zacks Research raised Inhibikase Therapeutics to a “hold” rating in a research report on Tuesday, December 2nd. Lifesci Capital upgraded Inhibikase Therapeutics to a “strong-buy” rating in a research note on Monday, December 1st. HC Wainwright upgraded shares of Inhibikase Therapeutics to a “strong-buy” rating in a research note on Friday, December 26th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a report on Wednesday, October 8th.

Get Our Latest Research Report on Inhibikase Therapeutics

Inhibikase Therapeutics Trading Down 3.3%

NASDAQ:IKT opened at $1.74 on Wednesday. The stock’s 50-day simple moving average is $1.67. The company has a market capitalization of $130.81 million, a P/E ratio of -4.46 and a beta of 0.84. Inhibikase Therapeutics has a one year low of $1.33 and a one year high of $3.32.

Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.13) earnings per share for the quarter.

About Inhibikase Therapeutics

(Get Free Report)

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.

Featured Articles